Literature DB >> 17089128

Blockade of STAT3 by antisense oligonucleotide in TNBS-induced murine colitis.

AiPing Bai1, PinJin Hu, Jie Chen, Xin Song, Wei Chen, WenXin Peng, ZhiRong Zeng, Xiang Gao.   

Abstract

BACKGROUND AND AIMS: The expression of signal transducers and activators of transcription 3 (STAT3) is increased in Crohn's disease (CD), and nuclear translocated STAT3 is also found in the disease. However, the role of STAT3 protein on the pathogenesis of CD is not clear. This study was executed to investigate the role of STAT3 protein on the pathogenesis of trinitrobenzene sulfonic acid (TNBS)-induced colitis, the pathogenesis of which is CD-like.
METHODS: TNBS-induced colitis was produced, and STAT3 antisense oligonucleotide was administrated intracolonically during the early phase of colitis. The mice were killed 7 days later, and the expressions of STAT3 and phosphorylated STAT3 were identified by Western blot and immunofluorescence. The lamina propria mononuclear cells (LPMCs) were isolated freshly, and the percent of cell death and the expressions of Bcl-2 and Bax in LPMCs were evaluated. Colonic tissue damage and the production of inflammatory cytokines were measured also.
RESULTS: Administration of STAT3 antisense oligonucleotide effectively inhibited STAT3 expression and phosphorylation in inflamed colonic mucosa of colitis. The mice that were administered STAT3 antisense oligonucleotide showed less colonic tissue damage with decreased production of inflammatory cytokines such as TNF-alpha and INF-gamma in mucosa compared with that of those TNBS-induced colitis. Administration of STAT3 antisense oligonucleotide successfully induced apoptosis of LPMCs and counteracted the unbalanced expressions of Bcl-2 and Bax in LPMCs from colitis.
CONCLUSIONS: STAT3 activation may play an important role in the inflammatory process of TNBS-induced colitis, and inhibiting STAT3 activation during the early phase of the inflammatory response may have a beneficial effect on the colitis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17089128     DOI: 10.1007/s00384-006-0229-z

Source DB:  PubMed          Journal:  Int J Colorectal Dis        ISSN: 0179-1958            Impact factor:   2.571


  40 in total

1.  STAT3 regulates the growth and immunoglobulin production of BCL(1) B cell lymphoma through control of cell cycle progression.

Authors:  J G Karras; R A McKay; T Lu; J Pych; D A Frank; T L Rothstein; B P Monia
Journal:  Cell Immunol       Date:  2000-06-15       Impact factor: 4.868

Review 2.  Social controls on cell survival and cell death.

Authors:  M C Raff
Journal:  Nature       Date:  1992-04-02       Impact factor: 49.962

3.  Characterization of a potent and specific class of antisense oligonucleotide inhibitor of human protein kinase C-alpha expression.

Authors:  R A McKay; L J Miraglia; L L Cummins; S R Owens; H Sasmor; N M Dean
Journal:  J Biol Chem       Date:  1999-01-15       Impact factor: 5.157

Review 4.  The proto-oncogene Bcl-2 and its role in regulating apoptosis.

Authors:  G Kroemer
Journal:  Nat Med       Date:  1997-06       Impact factor: 53.440

5.  Induction of the cytokine signal regulator SOCS3/CIS3 as a therapeutic strategy for treating inflammatory arthritis.

Authors:  T Shouda; T Yoshida; T Hanada; T Wakioka; M Oishi; K Miyoshi; S Komiya; K Kosai; Y Hanakawa; K Hashimoto; K Nagata; A Yoshimura
Journal:  J Clin Invest       Date:  2001-12       Impact factor: 14.808

6.  Therapeutic effect of intracolonically administered nuclear factor kappa B (p65) antisense oligonucleotide on mouse dextran sulphate sodium (DSS)-induced colitis.

Authors:  M Murano; K Maemura; I Hirata; K Toshina; T Nishikawa; N Hamamoto; S Sasaki; O Saitoh; K Katsu
Journal:  Clin Exp Immunol       Date:  2000-04       Impact factor: 4.330

7.  STAT3 deletion during hematopoiesis causes Crohn's disease-like pathogenesis and lethality: a critical role of STAT3 in innate immunity.

Authors:  Thomas Welte; Samuel S M Zhang; Tian Wang; Zhiyuan Zhang; David G T Hesslein; Zhinan Yin; Arihiro Kano; Yoshiki Iwamoto; En Li; Joseph E Craft; Alfred L M Bothwell; Erol Fikrig; Pandelakis A Koni; Richard A Flavell; Xin-Yuan Fu
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-05       Impact factor: 11.205

8.  Interleukin-6 (IL-6) prevents activation-induced cell death: IL-2-independent inhibition of Fas/fasL expression and cell death.

Authors:  E Ayroldi; O Zollo; L Cannarile; F D' Adamio; U Grohmann; D V Delfino; C Riccardi
Journal:  Blood       Date:  1998-12-01       Impact factor: 22.113

9.  Abrogated lymphocyte infiltration and lowered CD14 in dextran sulfate induced colitis in mice treated with p65 antisense oligonucleotides.

Authors:  Ann-Kristin Spiik; Anna Ridderstad; Lars-Göran Axelsson; Tore Midtvedt; Lars Björk; Sven Pettersson
Journal:  Int J Colorectal Dis       Date:  2002-02-20       Impact factor: 2.571

10.  Altered Th1/Th2 cytokine profiles in the intestinal mucosa of patients with inflammatory bowel disease as assessed by quantitative reversed transcribed polymerase chain reaction (RT-PCR).

Authors:  M Niessner; B A Volk
Journal:  Clin Exp Immunol       Date:  1995-09       Impact factor: 4.330

View more
  12 in total

Review 1.  Targeting key transcriptional factor STAT3 in colorectal cancer.

Authors:  Gayathri Chalikonda; Hoomin Lee; Aliya Sheik; Yun Suk Huh
Journal:  Mol Cell Biochem       Date:  2021-04-18       Impact factor: 3.396

2.  Oral treatment with SEW2871, a sphingosine-1-phosphate type 1 receptor agonist, ameliorates experimental colitis in interleukin-10 gene deficient mice.

Authors:  J Dong; H Wang; G Wu; J Zhao; L Zhang; L Zuo; W Zhu; J Gong; Y Li; L Gu; J Li
Journal:  Clin Exp Immunol       Date:  2014-07       Impact factor: 4.330

3.  Nicotine protects against DSS colitis through regulating microRNA-124 and STAT3.

Authors:  Zhen Qin; Jing-Jing Wan; Yang Sun; Tingyu Wu; Peng-Yuan Wang; Peng Du; Ding-Feng Su; Yili Yang; Xia Liu
Journal:  J Mol Med (Berl)       Date:  2016-10-05       Impact factor: 4.599

4.  Protective and therapeutic effect of apocynin on bleomycin-induced lung fibrosis in rats.

Authors:  Talat Kilic; Hakan Parlakpinar; Elif Taslidere; Sedat Yildiz; Alaadin Polat; Nigar Vardi; Cemil Colak; Hilal Ermis
Journal:  Inflammation       Date:  2015       Impact factor: 4.092

Review 5.  Nanomedicine and drug delivery strategies for treatment of inflammatory bowel disease.

Authors:  Hidetoshi Takedatsu; Keiichi Mitsuyama; Takuji Torimura
Journal:  World J Gastroenterol       Date:  2015-10-28       Impact factor: 5.742

Review 6.  JAK-STAT pathway targeting for the treatment of inflammatory bowel disease.

Authors:  Azucena Salas; Cristian Hernandez-Rocha; Marjolijn Duijvestein; William Faubion; Dermot McGovern; Severine Vermeire; Stefania Vetrano; Niels Vande Casteele
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-03-19       Impact factor: 46.802

7.  Modulation of inflammatory response via alpha2-adrenoceptor blockade in acute murine colitis.

Authors:  A Bai; N Lu; Y Guo; J Chen; Z Liu
Journal:  Clin Exp Immunol       Date:  2009-02-04       Impact factor: 4.330

Review 8.  Phytochemicals Targeting JAK-STAT Pathways in Inflammatory Bowel Disease: Insights from Animal Models.

Authors:  Sun Young Moon; Kwang Dong Kim; Jiyun Yoo; Jeong-Hyung Lee; Cheol Hwangbo
Journal:  Molecules       Date:  2021-05-10       Impact factor: 4.411

9.  Beneficial effect of shikonin on experimental colitis induced by dextran sulfate sodium in BALB/c mice.

Authors:  Isabel Andújar; José Luis Ríos; Rosa María Giner; José Miguel Cerdá; María Del Carmen Recio
Journal:  Evid Based Complement Alternat Med       Date:  2012-12-31       Impact factor: 2.629

Review 10.  Targeting STAT3 with Proteolysis Targeting Chimeras and Next-Generation Antisense Oligonucleotides.

Authors:  Jamie V Shiah; Jennifer R Grandis; Daniel E Johnson
Journal:  Mol Cancer Ther       Date:  2020-11-17       Impact factor: 6.009

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.